PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RPRX vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RPRX and LLY is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

RPRX vs. LLY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%AugustSeptemberOctoberNovemberDecember2025
3.23%
-16.82%
RPRX
LLY

Key characteristics

Sharpe Ratio

RPRX:

-0.10

LLY:

0.86

Sortino Ratio

RPRX:

0.01

LLY:

1.39

Omega Ratio

RPRX:

1.00

LLY:

1.18

Calmar Ratio

RPRX:

-0.04

LLY:

1.07

Martin Ratio

RPRX:

-0.20

LLY:

2.85

Ulcer Index

RPRX:

10.98%

LLY:

9.07%

Daily Std Dev

RPRX:

21.69%

LLY:

30.04%

Max Drawdown

RPRX:

-49.68%

LLY:

-68.27%

Current Drawdown

RPRX:

-46.04%

LLY:

-19.32%

Fundamentals

Market Cap

RPRX:

$15.03B

LLY:

$694.27B

EPS

RPRX:

$2.54

LLY:

$9.26

PE Ratio

RPRX:

10.04

LLY:

83.37

PEG Ratio

RPRX:

5.54

LLY:

0.73

Total Revenue (TTM)

RPRX:

$1.67B

LLY:

$31.51B

Gross Profit (TTM)

RPRX:

$1.08B

LLY:

$25.63B

EBITDA (TTM)

RPRX:

$1.47B

LLY:

$9.48B

Returns By Period

In the year-to-date period, RPRX achieves a 2.08% return, which is significantly higher than LLY's 0.17% return.


RPRX

YTD

2.08%

1M

0.50%

6M

3.23%

1Y

-3.97%

5Y*

N/A

10Y*

N/A

LLY

YTD

0.17%

1M

-6.46%

6M

-16.82%

1Y

24.33%

5Y*

43.59%

10Y*

29.69%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RPRX vs. LLY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RPRX
The Risk-Adjusted Performance Rank of RPRX is 3939
Overall Rank
The Sharpe Ratio Rank of RPRX is 4242
Sharpe Ratio Rank
The Sortino Ratio Rank of RPRX is 3333
Sortino Ratio Rank
The Omega Ratio Rank of RPRX is 3333
Omega Ratio Rank
The Calmar Ratio Rank of RPRX is 4545
Calmar Ratio Rank
The Martin Ratio Rank of RPRX is 4343
Martin Ratio Rank

LLY
The Risk-Adjusted Performance Rank of LLY is 7474
Overall Rank
The Sharpe Ratio Rank of LLY is 7676
Sharpe Ratio Rank
The Sortino Ratio Rank of LLY is 7070
Sortino Ratio Rank
The Omega Ratio Rank of LLY is 6969
Omega Ratio Rank
The Calmar Ratio Rank of LLY is 8181
Calmar Ratio Rank
The Martin Ratio Rank of LLY is 7373
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RPRX vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RPRX, currently valued at -0.10, compared to the broader market-4.00-2.000.002.00-0.100.86
The chart of Sortino ratio for RPRX, currently valued at 0.01, compared to the broader market-4.00-2.000.002.004.000.011.39
The chart of Omega ratio for RPRX, currently valued at 1.00, compared to the broader market0.501.001.502.001.001.18
The chart of Calmar ratio for RPRX, currently valued at -0.04, compared to the broader market0.002.004.006.00-0.041.07
The chart of Martin ratio for RPRX, currently valued at -0.20, compared to the broader market-10.000.0010.0020.00-0.202.85
RPRX
LLY

The current RPRX Sharpe Ratio is -0.10, which is lower than the LLY Sharpe Ratio of 0.86. The chart below compares the historical Sharpe Ratios of RPRX and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00AugustSeptemberOctoberNovemberDecember2025
-0.10
0.86
RPRX
LLY

Dividends

RPRX vs. LLY - Dividend Comparison

RPRX's dividend yield for the trailing twelve months is around 3.23%, more than LLY's 0.67% yield.


TTM20242023202220212020201920182017201620152014
RPRX
Royalty Pharma plc
3.23%3.29%2.85%1.92%1.71%0.60%0.00%0.00%0.00%0.00%0.00%0.00%
LLY
Eli Lilly and Company
0.67%0.67%0.78%1.07%1.23%1.75%1.96%1.95%2.46%2.77%2.37%2.84%

Drawdowns

RPRX vs. LLY - Drawdown Comparison

The maximum RPRX drawdown since its inception was -49.68%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for RPRX and LLY. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-46.04%
-19.32%
RPRX
LLY

Volatility

RPRX vs. LLY - Volatility Comparison

The current volatility for Royalty Pharma plc (RPRX) is 5.79%, while Eli Lilly and Company (LLY) has a volatility of 6.59%. This indicates that RPRX experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%16.00%AugustSeptemberOctoberNovemberDecember2025
5.79%
6.59%
RPRX
LLY

Financials

RPRX vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Royalty Pharma plc and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab